890 related articles for article (PubMed ID: 17408458)
1. World Health Organization classification in combination with cytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysplastic syndromes.
Bernasconi P; Klersy C; Boni M; Cavigliano PM; Calatroni S; Giardini I; Rocca B; Zappatore R; Caresana M; Dambruoso I; Lazzarino M; Bernasconi C
Br J Haematol; 2007 May; 137(3):193-205. PubMed ID: 17408458
[TBL] [Abstract][Full Text] [Related]
2. Incidence and prognostic significance of karyotype abnormalities in de novo primary myelodysplastic syndromes: a study on 331 patients from a single institution.
Bernasconi P; Klersy C; Boni M; Cavigliano PM; Calatroni S; Giardini I; Rocca B; Zappatore R; Caresana M; Quarna J; Lazzarino M; Bernasconi C
Leukemia; 2005 Aug; 19(8):1424-31. PubMed ID: 15920496
[TBL] [Abstract][Full Text] [Related]
3. Validation of the new comprehensive cytogenetic scoring system (NCCSS) on 630 consecutive de novo MDS patients from a single institution.
Bernasconi P; Klersy C; Boni M; Cavigliano PM; Dambruoso I; Zappatore R
Am J Hematol; 2013 Feb; 88(2):120-9. PubMed ID: 23349006
[TBL] [Abstract][Full Text] [Related]
4. Comparison of five prognostic scoring systems, the French-American-British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: Results of a single-center analysis.
Müller-Berndorff H; Haas PS; Kunzmann R; Schulte-Mönting J; Lübbert M
Ann Hematol; 2006 Aug; 85(8):502-13. PubMed ID: 16715299
[TBL] [Abstract][Full Text] [Related]
5. [Study on prognostic significances of different cytogenetic risk categories in patients with primary myelodysplastic syndromes].
Qu SQ; Liu XP; Xu ZF; Zhang Y; Qin TJ; Zhang TJ; Cui R; Hao YS; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2011 Dec; 32(12):819-24. PubMed ID: 22339954
[TBL] [Abstract][Full Text] [Related]
6. [Chromosomal aberrations in myelodysplastic syndrome].
Ol'shanskaia IuV; Domracheva EV; Udovichenko AI; Vodinskaia LA; Zakharova AV; Parovichnikova EN; Tsvetaeva NV; Mikhaĭlova EA; Glasko EN; Kolosova LIu; Kokhno AN; Tikhonova LIu; Shitareva TV; Smirnova EA; Alimova GA; Shirin AD; Vinogradova OIu; Khoroshko ND; Savchenko VG
Ter Arkh; 2005; 77(7):27-33. PubMed ID: 16116905
[TBL] [Abstract][Full Text] [Related]
7. Cytogenetic characteristics and prognosis analysis in 231 myelodysplastic syndrome patients from a single institution.
Jung SW; Lee SY; Jekarl DW; Kim M; Lim J; Kim Y; Han K; Kim YJ; Cho SG; Song J
Leuk Res; 2011 Jun; 35(6):735-40. PubMed ID: 21146871
[TBL] [Abstract][Full Text] [Related]
8. Detection of risk groups in myelodysplastic syndromes. A multicenter study.
Belli C; Acevedo S; Bengio R; Arrossagaray G; Watman N; Rossi N; García J; Flores G; Goldztein S; Larripa I
Haematologica; 2002 Jan; 87(1):9-16. PubMed ID: 11801460
[TBL] [Abstract][Full Text] [Related]
9. A comparative review of classification systems in myelodysplastic syndromes (MDS).
Bennett JM
Semin Oncol; 2005 Aug; 32(4 Suppl 5):S3-10. PubMed ID: 16085011
[TBL] [Abstract][Full Text] [Related]
10. Cytogenetic characteristics of patients with signs and symptoms of myelodysplastic syndromes in the State of Pará, Brazil.
Pinto GR; Overal DJ; Moraes LS; Van Den Berg AV; Lemos JA; Smith Mde A; Burbano RR
Genet Mol Res; 2005 Mar; 4(1):18-30. PubMed ID: 15841432
[TBL] [Abstract][Full Text] [Related]
11. Risk factor analysis in myelodysplastic syndrome patients with del(20q): prognosis revisited.
Liu YC; Ito Y; Hsiao HH; Sashida G; Kodama A; Ohyashiki JH; Ohyashiki K
Cancer Genet Cytogenet; 2006 Nov; 171(1):9-16. PubMed ID: 17074585
[TBL] [Abstract][Full Text] [Related]
12. Is International Prognostic Scoring System (IPSS) still standard in predicting prognosis in patients with myelodysplastic syndrome? External validation of the WHO Classification-Based Prognostic Scoring System (WPSS) and comparison with IPSS.
Park MJ; Kim HJ; Kim SH; Kim DH; Kim SJ; Jang JH; Kim K; Kim WS; Jung CW
Eur J Haematol; 2008 Nov; 81(5):364-73. PubMed ID: 18637029
[TBL] [Abstract][Full Text] [Related]
13. Classification and scoring systems in myelodysplastic syndromes: a retrospective analysis of 311 patients.
Navarro I; Ruiz MA; Cabello A; Collado R; Ferrer R; Hueso J; Martinez J; Miguel A; Orero MT; Pérez P; Nolasco A; Carbonell F
Leuk Res; 2006 Aug; 30(8):971-7. PubMed ID: 16423393
[TBL] [Abstract][Full Text] [Related]
14. [Karyotypic and IPSS grouping of primary myelodysplastic syndromes patients: a comparison between FAB- and WHO-classification].
Yu MH; Liu SH; Shao YQ; Hao YS; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2004 Aug; 25(8):482-5. PubMed ID: 15555265
[TBL] [Abstract][Full Text] [Related]
15. Does cytogenetic evolution have any prognostic relevance in myelodysplastic syndromes? A study on 153 patients from a single institution.
Bernasconi P; Klersy C; Boni M; Cavigliano PM; Giardini I; Rocca B; Zappatore R; Dambruoso I; Calvello C; Caresana M; Lazzarino M
Ann Hematol; 2010 Jun; 89(6):545-51. PubMed ID: 20217086
[TBL] [Abstract][Full Text] [Related]
16. Clinical relevance of cytogenetics in myelodysplastic syndromes.
Bernasconi P; Boni M; Cavigliano PM; Calatroni S; Giardini I; Rocca B; Zappatore R; Dambruoso I; Caresana M
Ann N Y Acad Sci; 2006 Nov; 1089():395-410. PubMed ID: 17261783
[TBL] [Abstract][Full Text] [Related]
17. Partial and total monosomal karyotypes in myelodysplastic syndromes: comparative prognostic relevance among 421 patients.
Belli CB; Bengió R; Aranguren PN; Sakamoto F; Flores MG; Watman N; Nucifora E; Prates MV; Arbelbide J; Larripa I
Am J Hematol; 2011 Jul; 86(7):540-5. PubMed ID: 21674572
[TBL] [Abstract][Full Text] [Related]
18. Cytogenetic evolution correlates with poor prognosis in myelodysplastic syndrome.
Wang H; Wang XQ; Xu XP; Lin GW
Cancer Genet Cytogenet; 2010 Jan; 196(2):159-66. PubMed ID: 20082852
[TBL] [Abstract][Full Text] [Related]
19. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes.
Kao JM; McMillan A; Greenberg PL
Am J Hematol; 2008 Oct; 83(10):765-70. PubMed ID: 18645988
[TBL] [Abstract][Full Text] [Related]
20. Does MDS with der(1;7)(q10;p10) constitute a distinct risk group? A retrospective single institutional analysis of clinical/pathologic features compared to -7/del(7q) MDS.
Slovak ML; O'Donnell M; Smith DD; Gaal K
Cancer Genet Cytogenet; 2009 Sep; 193(2):78-85. PubMed ID: 19665067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
